Why Is TELIX PHARMACEUTICAL ADR (TLX) Stock Down Today?

Telix Pharmaceuticals ADRs (TLX) fell 10.22% to $10.02 on October 21, 2026. The decline followed the company’s release of third-quarter financial results, which showed revenue growth but prompted a revision to research and development spending guidance.

What Happened

Telix reported Q3 group revenue of $245 million, up 19% from $206 million in the same period last year. Precision medicine revenue increased 30% year over year to $201 million, driven by demand for Gozellix and Illuccix. The company reaffirmed its view that full-year 2026 revenue and other income will exceed $1 billion, tracking toward the upper end of its $950 million to $970 million guidance. However, Telix revised its R&D spend guidance to a range of $240 million to $260 million. The stock also printed four fresh 52-week lows on the date of the report.

What The Data Shows

The stock opened at $10.45, a 6.4% gap down from the prior close of $11.16. The session high was $10.45 at 7:00 AM ET, while the low reached $9.92 at 9:35 AM ET. Volume stood at 0.1 million shares, which is 0.3 times the three-month daily average. Fundamentals show a market cap of $3.7 billion and a P/E ratio of 117.0. Revenue growth over the trailing twelve months is 33.5%, with a net margin of 3.8% and a beta of 0.56. The 52-week range is $6.28 to $13.11. Over the last eight sessions, the stock had moved up 0.4% from $11.12 to $11.16. Darren Charlton, the Group CFO, bought shares on September 7, 2026. Recent insider filings show one buy totaling $20,000 and no sells in the last 90 days.

What To Watch

Analysts have maintained positive stances, with Wedbush reiterating an Outperform rating and a $22 price target. Investors will monitor how the revised R&D spend guidance impacts future margins and whether the stock stabilizes after hitting new 52-week lows.